Innovent’s IBI343 Shows Strong Efficacy in Phase III Study, Eyes Regulatory Approval
SAN FRANCISCO and SUZHOU, China, June 4, 2026 Innovent Biologics has announced a major breakthrough in precision oncology as...
M&A
Advertisement
CytomX and Regeneron Expand $4B Cancer Immunotherapy Alliance
SOUTH SAN FRANCISCO, California, USA, June 3, 2026 CytomX Therapeutics has announced a significant expansion of its strategic research...
Travere Licenses Civorebrutinib in $1.14B Kidney Disease Deal
SAN DIEGO, California, USA, June 2, 2026 Travere Therapeutics has significantly expanded its rare kidney disease pipeline through an...
Lilly’s Retevmo Cuts Recurrence Risk by 83% in NSCLC
INDIANAPOLIS, Indiana, May 31, 2026 Eli Lilly and Company has announced groundbreaking results from the pivotal Phase 3 LIBRETTO-432...
Hanmi and Lilly Strike $1.26 Billion Deal for Promising GLP-2 Drug Candidate Sonefpeglutide
SEOUL, South Korea, June 1, 2026 Hanmi Pharm. Co., Ltd. has entered into a landmark global licensing agreement with...
Advertisements
Pfizer and Innovent Forge $10.5B Global Oncology Alliance
NEW YORK, SAN FRANCISCO, and SUZHOU, China, May 28, 2026 Pfizer Inc. and Innovent Biologics have announced a landmark...
Lilly Acquires Curevo, LimmaTech and Vaccine Company
INDIANAPOLIS, United States, May 26, 2026 Eli Lilly and Company has announced three major biotechnology acquisitions aimed at significantly...
Fosun Pharma Signs Global Option Deal for AriBio’s AR1001
SHANGHAI and SEONGNAM-SI, South Korea, May 13, 2026 Fosun Pharma and AriBio announced the signing of an exclusive global...
Boehringer Expands Immunology Pipeline With Immunitas Deal
INGELHEIM, Germany and WALTHAM, Mass., May 12, 2026 Boehringer Ingelheim has entered into a global licensing agreement with Immunitas...
BMS and Hengrui Form $15 Billion Drug Development Alliance
SHANGHAI, China and PRINCETON, N.J., May 12, 2026 Hengrui Pharma and Bristol Myers Squibb (BMS) have announced a landmark...
Advertisement
